DadFinStart your free weekJohnson & Johnson (JNJ) stock score
$261.44 ▲ +1.93% today
Johnson & Johnson (JNJ) is a Drug Manufacturers - General company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 78.0 out of 100 on the Dad Score, a good reading that places the business ahead of 78% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #198 of 974. Its strongest axes are valuation, quality and growth; its weakest are price action and conviction.
Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →
The eight axes
Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.
Key numbers
What subscribers see on JNJ
- Value Score: is the price right for this business, the score the Value book is selected on.
- Trader Score: is it set up to move, refreshed every 15 minutes in the session.
- The full eight-axis breakdown, every input and its percentile.
- SEC filings, insider buying, earnings history and peers side by side.
- Whether it is in this week's published books, with the receipts.
Drug Manufacturers - General peers
| Stock | Company | Dad Score | Band |
|---|---|---|---|
| LLY | Eli Lilly and Company | 93.7 | strong |
| ABBV | AbbVie Inc. | 99.0 | strong |
| MRK | Merck & Co., Inc. | 93.1 | strong |
| NVS | Novartis AG | 97.2 | strong |
| AZN | AstraZeneca PLC | 84.6 | good |
| AMGN | Amgen Inc. | 97.1 | strong |
| GILD | Gilead Sciences, Inc. | 85.1 | strong |
| NVO | Novo Nordisk A/S | 49.7 | middling |
Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.